Mustang Bio Inc buy stratec
Start price
21.06.19
/
50%
€3.16
Target price
04.11.21
€6.13
Performance (%)
-35.38%
End price
05.11.21
€2.04
Summary
This prediction ended on 05.11.21 with a price of €2.04. Massive losses of -35.38% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Mustang Bio Inc | - | - | - | - |
| iShares Core DAX® | 0.476% | -0.039% | 13.342% | 17.330% |
| iShares Nasdaq 100 | 1.290% | 0.504% | 40.099% | 50.534% |
| iShares Nikkei 225® | 1.300% | -2.135% | 19.861% | 4.937% |
| iShares S&P 500 | 0.829% | 0.193% | 29.756% | 43.432% |
Comments by stratec for this prediction
In the thread Mustang Bio Inc diskutieren
Mustang with positive data for a lentiviral gene therapy
The FDA designates Mustang Bio's (MBIO +0.8%) CAR-T candidate MB-102 an Orphan Drug for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and incurable blood cancer with a median survival of less than 18 months with no effective treatment options.
Es gibt keinen Handelsplatz
In the thread Trading Mustang Bio Inc
Die von stratec gewählte maximale Laufzeit wurde überschritten